February 18, 2026
1 min read

Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership

As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai Immunotherapeutics.

Leave a Reply

Your email address will not be published.

Previous Story

Want To Preserve Brain Health? Engage In A Lifetime Pursuit Of Knowledge, Study Says MedNews

Next Story

J&J fleshes out US investment plan, telegraphing $1B cell therapy plant and 500 new jobs in PA

Previous Story

Want To Preserve Brain Health? Engage In A Lifetime Pursuit Of Knowledge, Study Says MedNews

Next Story

J&J fleshes out US investment plan, telegraphing $1B cell therapy plant and 500 new jobs in PA

Latest from Blog

NEWS CENTER Maine

Through in-depth storytelling, through direct contact on digital on social platforms, through long-standing community service programs like Coats & Toys for Kids, Project Heat and Buddy to Buddy, NEWS CENTER Maine is
Go toTop